OrbiMed’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$33.6M Buy
114,700
+15,600
+16% +$5.13M 0.67% 45
2025
Q4
$34.7M Buy
+99,100
New +$33.5M 0.71% 44
2024
Q4
Sell
-106,200
Closed -$55.2M 124
2024
Q3
$55.2M Sell
106,200
-61,900
-37% -$33.1M 1% 29
2024
Q2
$91.1M Hold
168,100
1.8% 14
2024
Q1
$87.2M Buy
168,100
+26,600
+19% +$13.2M 1.6% 18
2023
Q4
$66.7M Buy
+141,500
New +$65.4M 1.33% 28
2021
Q4
Sell
-207,100
Closed -$77.2M 161
2021
Q3
$77.2M Sell
207,100
-128,600
-38% -$48.9M 0.85% 36
2021
Q2
$128M Buy
335,700
+49,100
+17% +$18.8M 1.3% 23
2021
Q1
$103M Sell
286,600
-23,900
-8% -$7.69M 0.96% 32
2020
Q4
$99.7M Buy
+310,500
New +$95.3M 0.87% 32
2020
Q1
Sell
-106,600
Closed -$32.2M 149
2019
Q4
$32.2M Sell
106,600
-148,000
-58% -$40.7M 0.46% 55
2019
Q3
$61.1M Sell
254,600
-107,000
-30% -$29.3M 1.16% 31
2019
Q2
$102M Buy
361,600
+36,400
+11% +$9.94M 1.58% 17
2019
Q1
$93.3M Buy
325,200
+19,800
+6% +$5.73M 1.44% 18
2018
Q4
$80.2M Sell
305,400
-168,600
-36% -$46.4M 1.48% 19
2018
Q3
$130M Sell
474,000
-57,800
-11% -$15M 1.56% 19
2018
Q2
$127M Buy
+531,800
New +$123M 1.51% 19
2018
Q1
Sell
-658,718
Closed -$148M 143
2017
Q4
$148M Sell
658,718
-268,900
-29% -$57.3M 1.87% 15
2017
Q3
$176M Buy
927,618
+7,000
+0.8% +$1.33M 1.68% 16
2017
Q2
$173M Buy
920,618
+58,018
+7% +$10.4M 1.82% 18
2017
Q1
$143M Sell
862,600
-159,000
-16% -$25.3M 1.62% 19
2016
Q4
$147M Buy
+1,021,600
New +$137M 1.87% 18
2015
Q1
Sell
-138,800
Closed -$17.4M 137
2014
Q4
$17.4M Buy
138,800
+20,300
+17% +$2.51M 0.17% 80
2014
Q3
$14.2M Buy
118,500
+58,500
+98% +$6.71M 0.15% 87
2014
Q2
$6.46M Buy
+60,000
New +$6.18M 0.08% 101
2014
Q1
Sell
-429,000
Closed -$39.6M 143
2013
Q4
$39.6M Sell
429,000
-777,000
-64% -$69M 0.58% 45
2013
Q3
$101M Buy
1,206,000
+19,000
+2% +$1.63M 1.8% 20
2013
Q2
$97.1M Buy
+1,187,000
New +$88.8M 2.06% 15

Other funds holding ELV

OrbiMed's ELV Position: Q1 2026 in Review

OrbiMed increased its Elevance Health (ELV) stake by 16% in Q1 2026, buying an estimated $5.13M and bringing the position to 114,700 shares worth $33.6M. The position accounts for 0.67% of the portfolio, ranked #45.

OrbiMed first reported a position in ELV in Q2 2013 and has held it in 28 quarters since. The position peaked at $176M in Q3 2017. 1,463 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • OrbiMed held 114,700 shares of Elevance Health worth $33.6M as of Q1 2026.
  • OrbiMed bought 15,600 Elevance Health shares in Q1 2026, an estimated $5.13M.
  • Elevance Health made up 0.67% of OrbiMed's portfolio in Q1 2026, its #45 holding.
  • OrbiMed first reported a position in Elevance Health in Q2 2013 and has held it in 28 quarters since.
  • OrbiMed's Elevance Health position peaked at $176M in Q3 2017.
  • 1,463 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.